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The turnaround times for conventional methods used to detectMycobacterium tuberculosis in sputum samples and to obtain
drug susceptibility information are long in many developing countries, including Panama, leading to delays in appropriate treat-
ment initiation and continued transmission in the community. We evaluated the performance of a molecular line probe assay,
the Genotype MTBDRplus version 2.0 assay, in detectingM. tuberculosis complex directly in respiratory specimens from smear-
positive tuberculosis cases from four different regions in Panama, as well as the most frequent mutations in genes conferring
resistance to isoniazid (katG and inhA) and rifampin (rpoB). Our results were confirmed with the nitrate reductase assay and
genomic sequencing.M. tuberculosis complex was detected by the Genotype MTBDRplus 2.0 assay with 100% sensitivity and
specificity. The sensitivity and specificity for rifampin resistance were 100% and 100%, respectively, and those for isoniazid re-
sistance were 90.7% and 100%. Isoniazid monoresistance was detected in 5.2% of new cases. GenotypeMTBDRplus 2.0 is highly
accurate in detectingM. tuberculosis complex in respiratory specimens and is able to discriminate isoniazid-monoresistant cases
frommultidrug-resistant cases within 2 days.
Novel diagnostic tools and their timely implementation in ar-eas in which disease is endemic are required tomake progress
toward the goal of reducing the global burden of tuberculosis (TB)
(1). In 2008, the World Health Organization (WHO) recom-
mended the use of molecular line probe assays (LPAs) for the
rapid detection of multidrug-resistant (MDR) TB (defined as TB
resistant to the first-line drugs isoniazid [INH] and rifampin
[RIF]). Two years later, the WHO endorsed the use of the Xpert
MTB/RIF assay for the rapid detection of MDR TB directly in
sputum samples (2); however, its relatively high cost has pre-
cluded its widespread use in resource-limited settings. The Geno-
type MTBDRplus 2.0 assay is one of the commercially available
LPAs that became available in February 2007 (3). Although this
assay has been evaluated and implemented in several countries, its
utility has not been formally evaluated in settings in Central
America with intermediate TB prevalence.
The primary tool for the diagnosis of pulmonary TB cases in
Panama, as in many countries, is staining of sputum samples for
acid-fast bacilli (AFB), using the Ziehl-Neelsen method. The Na-
tional Reference Laboratory (NRL) of Panama employs the Ca-
netti multiple-proportion method for drug susceptibility testing
(DST). The sensitivity of sputum AFB staining is approximately
50% and may be as low as 30% in HIV-infected patients (4, 5).
Additionally, the turnaround time for DST is at least 6 weeks. The
limited sensitivity and long delays for these traditional diagnostic
modalities promote the continued transmission of drug-suscepti-
ble and drug-resistant TB in the community (6). Only 113 MDR
cases were reported officially in Panama between 2001 and 2013
(7), although those figures are likely a gross underestimate of the
incidence of MDR TB, since DST is not routinely performed un-
less needed based on clinical grounds.
The effective use of a molecular technique applied directly to
sputum samples, with a rapid turnaround time, is needed to re-
duce transmission and to avoid outbreaks of MDR TB among
vulnerable populations (8). In this study, we evaluated and com-
pared the sensitivity and specificity of the Genotype MTBDRplus
2.0 assay, performed directly with AFB-positive respiratory spec-
imens, with conventional culture-based diagnostic methods and
DST.Genomic sequencing of all isolateswas performed to corrob-
orate the LPA results.
MATERIALS AND METHODS
Ethics statement.This studywas approved by the Bioethics Committee of
Panama.
Respiratory samples. Sixty-eight smear-positive specimens were col-
lected by the below-named individuals at six different hospitals from three
health regions in Panama with a high prevalence of LAM9-c1 MDR iso-
lates in the past decade (6), i.e., Manuel Amador Guerrero Hospital
(Colón region) (Mariela Vergara); Nuevo Veranillo Health Center (San
Miguelito region) (Silvana Campos); and Complejo Hospitalario Metro-
politanoDr.ArnulfoAriasMadrid (BertaMarshall), 24 deDiciembreHos-
pital (Julio Dominguez), Pueblo Nuevo Health Center (Delsa Pimentel),
and Santo Tomás Hospital (Erika Santiago) (all in the Panama City met-
ropolitan region). Most respiratory specimens were from pretreatment
cases and were collected between December 2012 and December 2013.
Due to financial constraints, smear-negative samples were not evaluated.
Sample processing and culture. Direct smears were prepared from
the specimens using Ziehl-Neelsen staining. Smears were read and inter-
preted in accordance with Pan American Health Organization (PAHO)
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guidelines (9). Specimens were decontaminated with the standard
N-acetyl-L-cysteine (NALC)-NaOHmethod (9), and the pellets were sus-
pended in 1.0 ml of phosphate buffer (pH 6.8). This was followed by
inoculation on Lowenstein-Jensen agar, and the residual portions of de-
contaminated samples were used to perform genomic extraction using a
Genolyse kit.
Biochemical characterization and drug susceptibility testing. After
incubation on Lowenstein-Jensen agar, isolates were classified as My-
cobacterium tuberculosis using biochemical assays, including assays of
nitrate reduction, niacin production, and catalase inhibition at 68°C.
DST was performed with all isolates using the nitrate reductase assay
(NRA) and the following critical concentrations of antibiotics: 0.2
g/ml isoniazid and 40 g/ml rifampin (10, 11). In cases with discor-
dant results from the LPA and NRA assays, the Canetti multiple-pro-
portion method was performed according to Panama National TB
Control Program guidelines (10), using the same antibiotic concen-
trations as for the NRA assay.
GenoTypeMTBDRplus 2.0 assay.TheGenotypeMTBDRplus version
2.0 test (Hain Lifescience, Germany) is based on DNA strip technology,
with three steps, i.e., DNA extraction, multiplex amplification with bio-
tinylated primers, and reverse hybridization, according to the manufac-
turer’s instructions (3). DNA extraction was performed with a Genolyse
kit, in three steps, i.e., centrifugation, lysis at 95°C, andneutralization. The
following amplification protocol was used for clinical specimens: 1 cycle
of 15 min at 95°C, 20 cycles of 30 s at 95°C and 2 min at 65°C, 30 cycles of
25 s at 95°C, 40 s at 50°C, and 40 s at 70°C, and finally 1 cycle of 8 min at
70°C. Reverse hybridizationwas performedwith an automated hybridiza-
tion system; an Auto-Lipa 48 system (Innogenetics) was used with the
reagents provided in the Genotype MTBDRplus 2.0 kit for the hybridiza-
tion procedure (3). Interpretation was performed according to the guide
included with the Genotype MTBDRplus kit. The absence of a wild-type
band and the presence of a mutant band for a specific gene on the strip
implied resistance.
Genomic sequencing. Mycobacterial isolates were sequenced with
an Illumina HiSeq 2500 instrument, using a paired-end sequencing
strategy. DNA samples were extracted from colonies using a QIAamp
DNA minikit, sheared into 250-bp fragments using a Covaris soni-
cator (Covaris, Inc.), and prepared using a standard whole-genome
DNA sequencing sample preparation kit (Illumina, Inc.). Paired-end
reads of 72 bp were collected. Base calling was performed using OLB
1.9.3 (Illumina, Inc.). Genome assembly was performed using custom
software that implements a comparative assembly approach (12) by
aligning reads with the genome sequence of M. tuberculosis H37Rv
(GenBank accession no. NC_000962.2). The mean depth of coverage
over the genome averaged 68-fold over all samples (range, 9.8-fold to
125.6-fold). A local contig-building algorithm was used to identify
indels (insertions or deletions) in regions where coverage was low.
RESULTS
Demographic data. During the period of December 2012 to De-
cember 2013, 68 smear-positive respiratory samples were col-
lected as part of routine TB diagnostic evaluations (Table 1). The
majority of samples were from the region of Colón (40/68 samples
[58.8%]) or the Panama City metropolitan area (23/68 samples
[33.8%]); 5/68 samples (7.4%) were from the San Miguelito re-
gion. The majority of samples (45/68 samples [66%]) were from
male subjects. The age range of the subjects was 16 to 90 years,
although there were two peaks in the age distribution (18 to 27
years and 48 to 57 years), and the mean age was 42 17.13 years.
Ten patients (14.7%) had a history of previous TB treatment,
while 58 cases (85.3%) were new TB cases. Four subjects (5.8%)
were HIV infected, 33 subjects (48.5%) were not HIV infected,
and the HIV status was not known for 31 subjects (45.5%).
Respiratory specimen characteristics. Refrigeration times for
the samples varied from 1 to 40 days, due to the distance of some
institutions from the NRL. Fewer than one-half of the specimens
for which information was available (28/65 specimens [43%])
were refrigerated for 10 days or less prior to processing. Samples
were classified as mucopurulent, bloody, mucous, or salivary ac-
cording to the PAHO classification (9); the majority of samples
(37/68 samples [55%]) were determined to be mucous. The vol-
umes of expectorated specimens ranged from 0.5 ml to 4 ml, and
three specimens derived from bronchial aspirates ranged from 5
to 10 ml in volume. The most frequently collected volume was 1
ml (26/68 samples [38.2%]). All samples were subjected to acid-
fast smear examination, which revealed a range of bacillary loads,
as follows: scanty, 7/68 samples (10.3%); 1, 35/68 samples
(51.5%); 2, 13/68 samples (19.1%); 3, 13/68 samples (19.1%)
(Fig. 1).
Characterization ofM. tuberculosis complex. Of the 68 AFB
smear-positive respiratory specimens, 54 cultures that were
positive on Lowenstein-Jensen agar were obtained and classi-
fied as M. tuberculosis using biochemical assays, including as-
says of nitrate reduction, niacin production, and catalase inhi-
bition at 68°C (10). The results were confirmed genetically
TABLE 1 Demographic data (n  68)
Characteristic Finding
Age (mean [range]) (yr) 42 (16–90)
Sex (no. [%])
Female 23 (33.8)
Male 45 (66.1)
TB history (no. [%])
New case 58 (85.3)
Retreatment 10 (14.7)
HIV infected (no. [%])
Yes 4 (5.8)
No 33 (48.5)
Unknown 31 (45.5)
Health region (no. [%])
Colón 40 (58.8)
Panama City metropolitan 23 (33.8)
San Miguelito 5 (7.4)
FIG1 Respiratory specimen characteristics. Samples were classified according
to the PAHO classification (9). Colors refer to the proportions of specimens in
each quality category, which were graded as scanty, 1, 2, or 3 by acid-fast
staining.
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using DNA sequencing. In contrast, the Genotype MTBDRplus
2.0 assay identified M. tuberculosis complex in all 68 processed
respiratory samples, including the 14 samples for which myco-
bacteria did not grow on solid agar.
Drug susceptibility testing with nitrate reductase assay. The
nitrate reductase assay is used to detect antibiotic resistance fol-
lowing the addition of 1 mg/ml potassium nitrate to Lowenstein-
Jensen medium, as the reduction of nitrate can be detected by the
development of a reddish color after the addition of the Griess
reagent (11). The WHO recommends that the NRA be used di-
rectly on smear-positive sputum specimens or on M. tuberculosis
isolates grown on solid agar (13). Since nitrate reduction, rather
than grossly visible colonies, is used as an indicator of growth, the
NRA reduces the turnaround time for DST, compared to conven-
tional methods.
In the current study, all positive cultures were tested with
the NRA, which yielded the following results: 4 cultures were
isoniazid monoresistant, 1 was rifampin monoresistant, 6 were
MDR, and 42 were susceptible to both drugs. However, bacilli
were not cultivable for 14 samples. Four of those smear-posi-
tive samples were obtained following the initiation of treat-
ment, and the remaining 10 isolates were refrigerated for a
mean duration of 15.7 days, which perhaps contributed to re-
duced bacillary viability. Among the 14 samples that did not have
reportable phenotypic DST results, the GenotypeMTBDRplus 2.0
assay detected 2 with rifampinmonoresistance, while 12 were sus-
ceptible to both drugs.
Drug susceptibility testing with GenoType MTBDRplus 2.0.
GenotypeMTBDRplus 2.0 identified 5/68 isolates (7.4%) asMDR,
4/68 (5.8%) as isoniazidmonoresistant, and 4/68 (5.8%) as rifam-
pin monoresistant. The C15T inhAmutation was the only mu-
tation detected in all 4 isoniazid-monoresistant isolates. Rifam-
pin-monoresistant samples displayed two types of mutations, i.e.,
the rpoB gene mutations H526D (3/4 isolates) and S531L (1/4
isolates). In contrast, mutations detected in MDR isolates were
rpoB S531L/katG S315T (4/5 isolates) and rpoB S531L/inhA
C15T (1/5 isolates) (Table 2). Among the 42 culture-positive
samples found to be drug susceptible by the NRA, Genotype
MTBDRplus 2.0 did not detect anymutation in the hotspots of the
genes rpoB, katG, or inhA.
Relative to conventional DST, the Genotype MTBDRplus
2.0 assay yielded a sensitivity, specificity, positive predictive
value, and negative predictive value of 100%, 100%, 100%, and
100%, respectively, for rifampin resistance. The sensitivity,
specificity, positive predictive value, and negative predictive
value of the Genotype MTBDRplus 2.0, relative to DST, were
90.9%, 100%, 100%, and 50%, respectively, for isoniazid resis-
tance.
Genomic sequencing. For three samples, the extracted DNA
concentration was below the threshold for performing sequenc-
ing. Genomic sequencing was performed for all culture-positive
samples and revealed 3 INH-monoresistant strains, 1 RIF-
monoresistant strain, and 4 MDR strains. The sensitivity and
specificity of the Genotype MTBDRplus 2.0 assay, compared to
genomic sequencing, were 87.5% and 100% for isoniazid and
100% and 100% for rifampin, respectively. Table 3 shows the cor-
relation betweenGenotypeMTBDRplus 2.0, genomic sequencing,
and conventional DST results.
DISCUSSION
To our knowledge, our study is the first to evaluate the perfor-
mance of the Genotype MTBDRplus 2.0 assay applied directly
to respiratory specimens in Central America, a region of inter-
mediate TB endemicity. In Panama, AFB staining and culture-
based DST remain the primary tools for the diagnosis of pul-
monary TB and detection of drug resistance. Therefore,
parameters such as the quality of the specimen, volume, and
storage time are taken into consideration in interpreting mi-
croscopy and DST results (10). Importantly, in the current
study, the Genotype MTBDRplus 2.0 assay was able to detect
TB and drug resistance correctly regardless of sample volume
or refrigeration time, likely because of the increased sensitivity
of DNA amplification-based methods and the lack of require-
ment for the presence of viable and/or cultivable bacilli in re-
spiratory specimens.
Of the 10 patients with a history of TB treatment, 9 harbored
isolates with resistance to1 drug, while 1 isolate was sensitive to
both isoniazid and rifampin. Five (56%) of those patients had a
history of substance abuse (including cocaine, marijuana, and/or
alcohol abuse), and 2 patients wereHIV infected. In Panama, as in
many parts of the world, drug-resistant TB is prevalent among
homeless individuals and those with a history of illicit drug use,
TABLE 2 Band patterns of drug-resistant Mycobacterium tuberculosis isolates using Genotype MTBDRplus 2.0
Gene and banda Gene region or mutation
No. of isolates (%)
MDR (n 5) INH monoresistant (n 4) RIF monoresistant (n 4)
rpoB
WT7 526–529 0 (0) 0 (0) 3 (75)
WT8 530–533 5 (100) 0 (0) 1 (25)
MUT2B H526D 0 (0) 0 (0) 3 (75)
MUT3 S531L 5 (100) 0 (0) 1 (25)
katG
WT 315 4 (80) 0 (0) 0 (0)
MUT1 S315T1 4 (80) 0 (0) 0 (0)
inhA
WT1 15/16 1 (20) 4 (100) 0 (0)
MUT1 C15T 1 (20) 4 (100) 0 (0)
a WT, wild-type; MUT, mutant.
Lanzas et al.
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because such populations are less likely to adhere tomedical treat-
ment and are at increased risk for acquiring primary drug-resis-
tant TB infections (14, 15).
Among newly diagnosed, culture-confirmed, TB cases, 1
isolate (1.7%) wasMDR and 5.2% (3/58 isolates) were found to
have isoniazid monoresistance. The prevalence of isoniazid-
resistant TB among newly diagnosed cases ranges geographi-
cally from 5 to 25% (16). Although the treatment outcomes for
such cases remain unclear, several retrospective studies suggest
that further drug resistance is promoted in the community
when isoniazid resistance is not recognized and standard treat-
ment is provided (17–20). Interestingly, the C15T mutation,
which is significantly less common than the katG S315T muta-
tion in isoniazid-resistant isolates worldwide (21) and in Pan-
ama, was present in all 3 cases in our study, suggesting the
possibility of recent transmission.
The sensitivity of the Genotype MTBDRplus 2.0 assay for
isoniazid resistance (90.7%) in the current study was greater
than that in studies performed prior to 2007 (22), likely be-
cause the newer version of the assay analyzes the inhA locus in
addition to katG. The sensitivity of Genotype MTBDRplus 2.0
for isoniazid resistancemight be further improved by including
additional resistance mutations based on geographic distribu-
tion (23). Knowledge of the precise mutation conferring resis-
tance may be very useful clinically, particularly in the case of
isoniazid, as the inhA C15T mutation generally confers low-
level resistance, which may be overcome with higher doses of
isoniazid (24, 25). Moreover, this version has been evaluated
with smear-negative/culture-positive specimens, showing sen-
sitivities of 58% to 76% (26, 27).
The LPA and DST yielded concordant results for all 42 sus-
ceptible isolates. On the other hand, LPA and DST yielded
discordant results for two resistant cases. Sample 003-061 was
reported as sensitive to isoniazid by the Genotype MTBDRplus
2.0 assay and resistant by the NRA, which was confirmed by the
Canetti multiple-proportion method. Sequencing of this sam-
ple revealed the mutation Y337C in the katG gene. Enzymology
studies show that this mutation confers resistance by reducing
the efficiency of INH radical formation while maintaining cat-
alytic efficiency for the native catalase activity, similar to S315T
(28). Although it is not a commonly recognized mutation (29),
Y337C has been reported to confer INH resistance among non-
clustered isolates (30). Our previous studies revealed that ap-
proximately 16% of clustered MDR isolates identified in Pan-
ama over the past decade lacked mutations in the katG and
inhA loci (31). The second case with discordant results in-
volved isolate 044-04, which contained a C15T mutation de-
tected with the LPA, although an indeterminate reaction was
noted with the NRA. The Canetti multiple-proportion method
yielded the growth of a single isoniazid-resistant colony. Se-
quencing of this sample confirmed the LPA result. Interest-
ingly, this sample had been refrigerated for 18 days, which
suggests that there might have been loss of bacterial viability,
potentially accounting for the false-negative DST result.
The ability to detect very few resistant bacilli in a sputum
sample may represent an advantage of molecular drug suscep-
tibility testing. Although the current version of the Genotype
MTBDRplus 2.0 assay still cannot detect all INH resistance-con-
ferring mutations, it has a high sensitivity for detecting RIF resis-
tance and thus for identifyingMDR cases. Furthermore, the short
turnaround time of 2 days for producing TB drug susceptibility
results, compared to 2 to 3 months for standard, culture-based,
DST methods, is a major boon to facilitate clinical decision-mak-
ing and the selection of appropriate antitubercular therapy in real
time.
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